You are here

  • Home
  • Archive
  • Volume 65, Issue 6
  • Efficacy of nebulised colomycin in patients with non-cystic fibrosis bronchiectasis colonised with Pseudomonas aeruginosa

Article Text

Article menu

Download PDFPDF

PostScript
Letter
Efficacy of nebulised colomycin in patients with non-cystic fibrosis bronchiectasis colonised with Pseudomonas aeruginosa
Free
  1. R Dhar1,
  2. G A Anwar1,
  3. S C Bourke1,
  4. L Doherty1,
  5. P Middleton2,
  6. C Ward2,
  7. R M Rutherford1
  1. 1Northumbria Healthcare Trust, Tyne and Wear, UK
  2. 2Applied Immunobiology and Transplantation Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK
  1. Correspondence to Robert Rutherford, North Tyneside General Hospital, Rake Lane, North Shields, Tyne and Wear NE29 8NH, UK; bobrutherford87{at}yahoo.com

https://doi.org/10.1136/thx.2008.112284

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Colonisation with Pseudomonas aeruginosa is a feature of bronchiectasis and is associated with more severe disease and lower quality of life.1 Nebulised colomycin, a polymixin, bactericidal antibiotic with potent activity against most Gram-negative organisms, including P aeruginosa, is frequently employed in these patients, but evidence is lacking for this approach.

    We have retrospectively assessed the efficacy of nebulised colomycin in P aeruginosa-colonised patients receiving a minimum of 6 months treatment. Patients who received concomitant prophylactic macrolide treatment for >4 weeks were excluded. Bronchiectasis was confirmed in all patients by standard high-resolution CT criteria, and all received nebulised colomycin 1–2 megaunits twice daily through a standard jet nebuliser …

    View Full Text